Correction to: J Immunother Cancer
Following publication of the original article [1], the authors reported an error in their listed affiliations. This error was introduced during typesetting and the publisher apologizes to readers and the authors for the inconvenience.
In this Correction the authors are listed with their correct affiliations below.
Daniel H Johnson1, Chrystia M Zobniw2, Van A Trinh2, Junsheng Ma3, Roland L Bassett Jr3, Noha Abdel-Wahab4,5, Jaime Anderson2, Jennifer E Davis6, Jocelyn Joseph2, Marc Uemura1, Ali Noman7, Hamzah Abu-Sbeih7, Cassian Yee1, Rodabe Amaria1, Sapna Patel1, Hussein Tawbi1, Isabella C Glitza1, Michael A Davies1, Michael K Wong1, Scott Woodman1, Wen-Jen Hwu1, Patrick Hwu1, Yinghong Wang7 and Adi Diab1
1Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
2Division of Pharmacy, Clinical Section, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
3Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
4Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
5Department of Rheumatology and Rehabilitation, Faculty of Medicine, Assiut University Hospitals, Assiut, Egypt
6Department of Epidemiology, Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
7Department of Gastroenterology, Hepatology, and Nutrition, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Reference
Johnson DH, et al. Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. J Immunother Cancer. 2018;6:103 https://doi.org/10.1186/s40425-018-0412-0.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
About this article
Cite this article
Johnson, D.H., Zobniw, C.M., Trinh, V.A. et al. Correction to: Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. j. immunotherapy cancer 7, 107 (2019). https://doi.org/10.1186/s40425-018-0469-9
Received:
Accepted:
Published:
DOI: https://doi.org/10.1186/s40425-018-0469-9